End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,917 MXN | -3.26% |
|
-3.26% | +0.20% |
13/06 | Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 | MT |
07/06 | The job report just threw a spanner in the works | ![]() |
Evolution of the average Target Price on Charles River Laboratories International, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Charles River Laboratories International, Inc.
Baird | |
Mizuho Securities | |
TD Cowen | |
JPMorgan Chase | |
Jefferies & Co. | |
Evercore ISI | |
Zacks Investment Research | |
Deutsche Bank Securities | |
Argus | |
Morgan Stanley | |
Stephens Inc. | |
Citigroup | |
UBS | |
Guggenheim | |
Wells Fargo Securities | |
BofA Securities | |
Credit Suisse | |
KeyBanc Capital Markets | |
Truist Securities | |
Goldman Sachs | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- CRL Stock
- CRL * Stock
- Consensus Charles River Laboratories International, Inc.